|
Communication Can Minimize Study Disruptions During IRB Transfers: FDA
To smoothly transition clinical investigation oversight from one institutional review board to another, devicemakers, contract research organizations (CRO), new and old IRBs and clinical investigators should work closely to minimize disruptions to the ongoing trial and ensure subjects are constantly protected, according to an FDA draft guidance.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives